Dendrin ablation prolongs life span by delaying kidney failure

Area of Science:

• Nephrology
• Molecular Biology
• Genetics

Background:

• Podocyte loss is a primary driver of proteinuric kidney diseases, often leading to end-stage kidney disease (ESKD) and high mortality rates.
• Current treatments for ESKD, such as dialysis, have limited long-term efficacy, highlighting the need for novel therapeutic strategies targeting podocyte protection.

Purpose of the Study:

• To investigate the role of the podocyte death-promoting protein dendrin in the progression of kidney disease.
• To evaluate the therapeutic potential of ablating dendrin in preventing podocyte loss and delaying ESKD.

Main Methods:

• Utilized a mouse model lacking the CD2AP adapter protein to study kidney disease progression.
• Genetically ablated the dendrin gene in podocytes to assess its impact on disease onset and severity.
• Monitored proteinuria, podocyte counts, mesangial expansion, and fibronectin expression.

Main Results:

• Ablation of dendrin significantly delayed the onset and reduced the severity of proteinuria and podocyte loss.
• Dendrin ablation ameliorated mesangial volume expansion and suppressed the upregulation of mesangial fibronectin.
• The lifespan of mice lacking CD2AP was extended by dendrin ablation.

Conclusions:

• Dendrin plays a critical role in promoting podocyte death and driving kidney disease progression.
• Blocking dendrin function represents a promising therapeutic strategy to delay ESKD and improve patient outcomes.
• Targeting dendrin offers a novel approach to prevent podocyte loss in proteinuric kidney diseases.